The current FDA record is broader and more careful than the earlier article suggested. FDA materials address AI and machine learning across drug development, while the FDA and EMA published ten principles for good AI practice in January 2026. FDA's credibility framework focuses on whether an AI model is credible for a defined context of use; it is not blanket regulatory acceptance of AI-assisted clinical-trial design.
What the framework emphasises
Sponsors should define the question the model informs, assess the consequence of a wrong result, document data provenance and representativeness, select validation proportionate to risk, and manage performance through the model lifecycle. The required evidence depends on the model and intended use.
What organisations should avoid
Do not infer that use of AI is approved merely because a model performs well on a benchmark. Do not reuse a validation result outside the context for which it was produced. Patient, clinical, and regulatory decisions require qualified domain and legal review.
Operational takeaway
Maintain traceable model versions, datasets, assumptions, validation results, human responsibilities, and change controls. Engage the relevant regulator early when the model will materially inform a submission or trial decision. This article is general information, not medical or regulatory advice.
Sources & further reading
Follow the original evidence. Sources may include the organisation making the announcement; claims and independent findings are distinguished in the analysis.
01Good AI practice in drug development, FDA and EMAwww.fda.gov02AI and machine learning in drug development, FDAwww.fda.gov03Credibility framework for AI models in submissions, FDAwww.fda.govAI in Drug Development: What the Current FDA Framework Actually Requires
FDA and EMA materials emphasise context of use, risk-based credibility, data governance, and lifecycle monitoring; they do not provide blanket pre-approval for AI.
Last factual review: 24 August 2026